Skip to main content
Erschienen in: Drugs 13/2011

01.09.2011 | Adis Drug Evaluation

Dasatinib

A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia

verfasst von: Paul L. McCormack, Susan J. Keam

Erschienen in: Drugs | Ausgabe 13/2011

Einloggen, um Zugang zu erhalten

Abstract

Dasatinib (Sprycel®) is an orally administered small molecule inhibitor of multiple tyrosine kinases, including BCR-ABL and SRC family kinases, which is indicated for the treatment of adults with newly diagnosed chronic-phase chronic myeloid leukaemia (CML), CML (chronic-, accelerated-or blast-phase) with resistance or intolerance to prior therapy, including imatinib, or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy. Dasatinib is ≈325-fold more active than imatinib in inhibiting wild-type ABL kinase in vitro and is active against a wide variety of imatinib-resistant BCR-ABL mutants, except for T315I. This article reviews the efficacy and tolerability of dasatinib in the treatment of patients with newly diagnosed chronic-phase CML or imatinib-resistant or -intolerant CML or Ph+ ALL, as well as summarizing its pharmacological properties.
In clinical trials, oral dasatinib was effective in achieving major or complete cytogenetic responses in both newly diagnosed and imatinib-resistant or -intolerant chronic-phase CML. Dasatinib was likewise effective in achieving major or overall haematological responses in imatinib-resistant or -intolerant, accelerated-or blast-phase CML, or Ph+ ALL. Responses were rapidly achieved within 1–3 months and were durable over 1–5 years of follow-up. The majority of adverse events with dasatinib were of mild to moderate severity. Fluid retention (including pleural effusion) was the most common adverse event. Haematological abnormalities were common and cytopenias were the most common grade 3/4 adverse events. Dasatinib 100 mg administered once daily was as effective as dasatinib 70 mg administered twice daily, and was better tolerated, being associated with lower incidences of pleural effusion and grade 3/4 thrombocytopenia, in particular. Dasatinib was more effective than high-dose imatinib in the treatment of patients with imatinib-resistant chronic-phase CML and was more effective thanstandard dosages of imatinib, as well as being associated with less frequent fluid retention, in patients with newly diagnosed chronic-phase CML. Dasatinib was generally equally effective in patients with or without BCR-ABL mutations at baseline.
Therefore, oral dasatinib is a highly effective once-daily therapy for the first-line treatment of newly diagnosed patients with chronic-phase CML, as well as for the treatment of patients with imatinib-resistant or -intolerant chronic-and advanced-phase CML or Ph+ ALL.
Literatur
1.
Zurück zum Zitat Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 May; 20 Suppl. 4: 105–7PubMedCrossRef Baccarani M, Dreyling M. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 May; 20 Suppl. 4: 105–7PubMedCrossRef
2.
Zurück zum Zitat O’Brien S, Berman E, Borghaei H, et al. NCCN Clinical Practice Guidelines in Oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009 Oct; 7(9): 984–1023PubMed O’Brien S, Berman E, Borghaei H, et al. NCCN Clinical Practice Guidelines in Oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw 2009 Oct; 7(9): 984–1023PubMed
3.
Zurück zum Zitat Crazzolara R, Bendall L. Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets 2009; 9(1): 19–31PubMedCrossRef Crazzolara R, Bendall L. Emerging treatments in acute lymphoblastic leukemia. Curr Cancer Drug Targets 2009; 9(1): 19–31PubMedCrossRef
4.
Zurück zum Zitat Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs 2011; 71(4): 415–42PubMed Litzow MR. Pharmacotherapeutic advances in the treatment of acute lymphoblastic leukaemia in adults. Drugs 2011; 71(4): 415–42PubMed
5.
Zurück zum Zitat Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 Dec 10; 27(35): 6041–51PubMedCrossRef Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 Dec 10; 27(35): 6041–51PubMedCrossRef
6.
Zurück zum Zitat Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67(2): 299–320PubMedCrossRef Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67(2): 299–320PubMedCrossRef
7.
Zurück zum Zitat Kuznar W. New and emerging drugs for treatment-resistant CML. Am Health Drug Benefits 2009 Aug; 2(5): 22 Kuznar W. New and emerging drugs for treatment-resistant CML. Am Health Drug Benefits 2009 Aug; 2(5): 22
8.
Zurück zum Zitat Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 Dec 7; 355(23): 2408–17PubMedCrossRef Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 Dec 7; 355(23): 2408–17PubMedCrossRef
9.
Zurück zum Zitat Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004 Aug; 18(8): 1321–31PubMedCrossRef Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004 Aug; 18(8): 1321–31PubMedCrossRef
10.
Zurück zum Zitat Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010 Feb; 26(2): 307–17PubMedCrossRef Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010 Feb; 26(2): 307–17PubMedCrossRef
11.
Zurück zum Zitat Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Biodrugs 2008; 22(1): 59–69PubMedCrossRef Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Biodrugs 2008; 22(1): 59–69PubMedCrossRef
12.
13.
Zurück zum Zitat O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005 Jun 1; 65(11): 4500–5PubMedCrossRef O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005 Jun 1; 65(11): 4500–5PubMedCrossRef
15.
Zurück zum Zitat Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008 Jul 1; 26(19): 3204–12PubMedCrossRef Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008 Jul 1; 26(19): 3204–12PubMedCrossRef
16.
Zurück zum Zitat Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008 Jun 27; 283(26): 18292–302PubMedCrossRef Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008 Jun 27; 283(26): 18292–302PubMedCrossRef
17.
Zurück zum Zitat Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007 Apr; 6(4): 1400–5PubMedCrossRef Nam S, Williams A, Vultur A, et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007 Apr; 6(4): 1400–5PubMedCrossRef
18.
Zurück zum Zitat Dumka D, Puri P, Carayol N, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009 Dec; 50(12): 2017–29PubMedCrossRef Dumka D, Puri P, Carayol N, et al. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009 Dec; 50(12): 2017–29PubMedCrossRef
19.
Zurück zum Zitat Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006 Jun 1; 107(11): 4532–9PubMedCrossRef Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006 Jun 1; 107(11): 4532–9PubMedCrossRef
20.
Zurück zum Zitat Jørgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007 Nov; 35 (Pt 5): 1347–51PubMedCrossRef Jørgensen HG, Holyoake TL. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem Soc Trans 2007 Nov; 35 (Pt 5): 1347–51PubMedCrossRef
21.
Zurück zum Zitat Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011 Jan; 121(1): 396–409PubMedCrossRef Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011 Jan; 121(1): 396–409PubMedCrossRef
22.
Zurück zum Zitat Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009 Sep 1; 27(25): 4204–10PubMedCrossRef Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 2009 Sep 1; 27(25): 4204–10PubMedCrossRef
23.
Zurück zum Zitat Soverini S, Martinelli G, Colarossi S, et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 2007 Mar; 8(3): 273–4PubMedCrossRef Soverini S, Martinelli G, Colarossi S, et al. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncol 2007 Mar; 8(3): 273–4PubMedCrossRef
24.
Zurück zum Zitat Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 2009 Sep 3; 114(10): 2168–71PubMedCrossRef Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second-or third-line tyrosine kinase inhibitors. Blood 2009 Sep 3; 114(10): 2168–71PubMedCrossRef
25.
Zurück zum Zitat Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008 Aug 15; 112(4): 1005–12PubMedCrossRef Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008 Aug 15; 112(4): 1005–12PubMedCrossRef
26.
Zurück zum Zitat Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009 Nov; 338(5): 414–7PubMedCrossRef Goldblatt M, Huggins JT, Doelken P, et al. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci 2009 Nov; 338(5): 414–7PubMedCrossRef
27.
Zurück zum Zitat Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010 Jul; 16(4): 351–6PubMedCrossRef Brixey AG, Light RW. Pleural effusions due to dasatinib. Curr Opin Pulm Med 2010 Jul; 16(4): 351–6PubMedCrossRef
28.
Zurück zum Zitat Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007 Oct 15; 176(8): 814–8PubMedCrossRef Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007 Oct 15; 176(8): 814–8PubMedCrossRef
29.
Zurück zum Zitat de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008 May; 141(5): 745–7PubMedCrossRef de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008 May; 141(5): 745–7PubMedCrossRef
30.
Zurück zum Zitat Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009 Aug; 23(8): 1398–405PubMedCrossRef Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009 Aug; 23(8): 1398–405PubMedCrossRef
31.
Zurück zum Zitat Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010 Aug 5; 116(5): 772–82PubMedCrossRef Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010 Aug 5; 116(5): 772–82PubMedCrossRef
32.
Zurück zum Zitat Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011 Apr; 52(4): 668–79PubMedCrossRef Powers JJ, Dubovsky JA, Epling-Burnette PK, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2011 Apr; 52(4): 668–79PubMedCrossRef
33.
Zurück zum Zitat Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007 Aug 14; 104(33): 13283–8PubMedCrossRef Hantschel O, Rix U, Schmidt U, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007 Aug 14; 104(33): 13283–8PubMedCrossRef
34.
Zurück zum Zitat Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008 Feb 1; 111(3): 1366–77PubMedCrossRef Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008 Feb 1; 111(3): 1366–77PubMedCrossRef
35.
Zurück zum Zitat Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008 Apr 15; 14(8): 2484–91PubMedCrossRef Weichsel R, Dix C, Wooldridge L, et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008 Apr 15; 14(8): 2484–91PubMedCrossRef
36.
Zurück zum Zitat Blake SJ, Lyons AB, Fraser CK, et al. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008 Apr 15; 111(8): 4415–6PubMedCrossRef Blake SJ, Lyons AB, Fraser CK, et al. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood 2008 Apr 15; 111(8): 4415–6PubMedCrossRef
37.
Zurück zum Zitat Gratacap M-P, Martin V, Valéra M-C, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009 Aug 27; 114(9): 1884–92PubMedCrossRef Gratacap M-P, Martin V, Valéra M-C, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009 Aug 27; 114(9): 1884–92PubMedCrossRef
38.
Zurück zum Zitat Nicaise C, Wang X, Roy A, et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase [abstract no. 0559]. Haematologica 2008 Jun; 93 Suppl. 1: 227 Nicaise C, Wang X, Roy A, et al. Dasatinib pharmacokinetics and exposure-response: relationships to efficacy and safety in patients with chronic myelogenous leukemia in chronic phase [abstract no. 0559]. Haematologica 2008 Jun; 93 Suppl. 1: 227
39.
Zurück zum Zitat Rousselot P, Bouchet S, Etienne G, et al. Early cytogenetic and molecular responses and pharmacokinetic of dasatinib as a first line therapy in newly diagnosed chronic phase CML patients: first analysis of the OPTIM dasatinib trial [abstract no. 1139]. 15th Congress of the European Hematology Association; 2010 Jun 10–13; Barcelona Rousselot P, Bouchet S, Etienne G, et al. Early cytogenetic and molecular responses and pharmacokinetic of dasatinib as a first line therapy in newly diagnosed chronic phase CML patients: first analysis of the OPTIM dasatinib trial [abstract no. 1139]. 15th Congress of the European Hematology Association; 2010 Jun 10–13; Barcelona
40.
Zurück zum Zitat Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010 Feb; 95(2): 232–40PubMedCrossRef Shah NP, Kim D-W, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010 Feb; 95(2): 232–40PubMedCrossRef
41.
Zurück zum Zitat Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009 Sep 15; 115(18): 4136–47PubMedCrossRef Kantarjian H, Pasquini R, Lévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009 Sep 15; 115(18): 4136–47PubMedCrossRef
42.
Zurück zum Zitat Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010 Aug 15; 116(16): 3852–61PubMedCrossRef Saglio G, Hochhaus A, Goh YT, et al. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 2010 Aug 15; 116(16): 3852–61PubMedCrossRef
43.
Zurück zum Zitat Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010 Mar; 85(3): 164–70PubMed Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol 2010 Mar; 85(3): 164–70PubMed
44.
Zurück zum Zitat Apperley JF, Cortes JE, Kim D-W, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009; 27(21): 3472–9PubMedCrossRef Apperley JF, Cortes JE, Kim D-W, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009; 27(21): 3472–9PubMedCrossRef
45.
Zurück zum Zitat Kantarjian H, Cortes J, Kim D-W, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009 Jun 18; 113(25): 6322–9PubMedCrossRef Kantarjian H, Cortes J, Kim D-W, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009 Jun 18; 113(25): 6322–9PubMedCrossRef
46.
Zurück zum Zitat Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007 Oct 1; 110(7): 2309–15PubMedCrossRef Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007 Oct 1; 110(7): 2309–15PubMedCrossRef
47.
Zurück zum Zitat Cortes J, Kim D-W, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22(12): 2176–83PubMedCrossRef Cortes J, Kim D-W, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008; 22(12): 2176–83PubMedCrossRef
48.
Zurück zum Zitat Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22(6): 1200–6PubMedCrossRef Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22(6): 1200–6PubMedCrossRef
49.
Zurück zum Zitat Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010 Jun 17; 362(24): 2260–70PubMedCrossRef Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010 Jun 17; 362(24): 2260–70PubMedCrossRef
50.
Zurück zum Zitat Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008 Jul; 36(7): 1357–64PubMedCrossRef Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos 2008 Jul; 36(7): 1357–64PubMedCrossRef
51.
Zurück zum Zitat Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009 Jun; 49(6): 700–9PubMedCrossRef Eley T, Luo FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol 2009 Jun; 49(6): 700–9PubMedCrossRef
52.
Zurück zum Zitat Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 Jun 15; 354(24): 2531–41PubMedCrossRef Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 Jun 15; 354(24): 2531–41PubMedCrossRef
53.
Zurück zum Zitat Radich JP, Kopecky Kj, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): the SO325 Intergroup trial [Abstract no. LBA-6 plus oral presentation]. 52nd Annual Meeting of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL) Radich JP, Kopecky Kj, Kamel-Reid S, et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP): the SO325 Intergroup trial [Abstract no. LBA-6 plus oral presentation]. 52nd Annual Meeting of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL)
54.
Zurück zum Zitat Cervantes F, Baccarani M, Lipton J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase with resistance or intolerance to imatinib: a two-year update of the START-C study [abstract no. 0934]. Haematologica 2008 Jun; 93 Suppl. 1: 372 Cervantes F, Baccarani M, Lipton J, et al. Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase with resistance or intolerance to imatinib: a two-year update of the START-C study [abstract no. 0934]. Haematologica 2008 Jun; 93 Suppl. 1: 372
55.
Zurück zum Zitat Saglio G, Cortes JE, Schiffer CA, et al. Long-term efficacy and safety of dasatinib 100 mg once-daily (QD) in patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP): 5-year follow-up from CA180-034 [poster 0136]. 16th Congress of the European Hematology Association; 2011 Jun 9–12; London Saglio G, Cortes JE, Schiffer CA, et al. Long-term efficacy and safety of dasatinib 100 mg once-daily (QD) in patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP): 5-year follow-up from CA180-034 [poster 0136]. 16th Congress of the European Hematology Association; 2011 Jun 9–12; London
56.
Zurück zum Zitat Shah N, Kantarjian HM, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase in the DASISION trial: 18-month follow-up [abstract no. 206]. 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL) Shah N, Kantarjian HM, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase in the DASISION trial: 18-month follow-up [abstract no. 206]. 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4–7; Orlando (FL)
57.
Zurück zum Zitat Hochhaus A, Shah N, Cortes J, et al. Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic plase (CML-CP): minimum 24-month follow-up from the DASISION trial [abstract no. 1011]. Haematologica 2011; 96 Suppl. 2: 422. Plus oral presentation at the 16th Congress of the European Hematology Association; 2011 Jun 9–12; London Hochhaus A, Shah N, Cortes J, et al. Efficacy and safety of dasatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic plase (CML-CP): minimum 24-month follow-up from the DASISION trial [abstract no. 1011]. Haematologica 2011; 96 Suppl. 2: 422. Plus oral presentation at the 16th Congress of the European Hematology Association; 2011 Jun 9–12; London
58.
Zurück zum Zitat Cortes J, Rousselot P, Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 Apr 15; 109(8): 3207–13PubMedCrossRef Cortes J, Rousselot P, Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 Apr 15; 109(8): 3207–13PubMedCrossRef
59.
Zurück zum Zitat Porkka K, Martinelli G, Ottman OG, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L [abstract no. 0001]. Haematologica 2008 Jun 1; 93 Suppl. 1: 1CrossRef Porkka K, Martinelli G, Ottman OG, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L [abstract no. 0001]. Haematologica 2008 Jun 1; 93 Suppl. 1: 1CrossRef
60.
Zurück zum Zitat Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant for-intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035 [abstract no. 2926]. Blood 2008; 112 (11) Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with imatinib-resistant for-intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035 [abstract no. 2926]. Blood 2008; 112 (11)
61.
Zurück zum Zitat Quintás-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007 Sep 1; 25(25): 3908–14PubMedCrossRef Quintás-Cardama A, Kantarjian H, O’Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007 Sep 1; 25(25): 3908–14PubMedCrossRef
62.
Zurück zum Zitat Porkka K, Baccarani M, Cortes J, et al. Pleural effusion in patients with chronic-phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: patient characteristics, management and outcomes [poster no. 0692]. 16th Congress of the European Hematology Association; 2011 Jun 9–12; London Porkka K, Baccarani M, Cortes J, et al. Pleural effusion in patients with chronic-phase chronic myeloid leukemia (CML-CP) who received first-line dasatinib in the DASISION trial: patient characteristics, management and outcomes [poster no. 0692]. 16th Congress of the European Hematology Association; 2011 Jun 9–12; London
63.
Zurück zum Zitat Peggs K, Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348(11): 1048–50PubMedCrossRef Peggs K, Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348(11): 1048–50PubMedCrossRef
64.
Zurück zum Zitat Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008 Jan 15; 14(2): 352–9PubMedCrossRef Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008 Jan 15; 14(2): 352–9PubMedCrossRef
65.
Zurück zum Zitat Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001 Oct 1; 98(7): 2039–42PubMedCrossRef Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001 Oct 1; 98(7): 2039–42PubMedCrossRef
66.
Zurück zum Zitat Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 Sep 15; 108(6): 1809–20PubMedCrossRef Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 Sep 15; 108(6): 1809–20PubMedCrossRef
67.
Zurück zum Zitat O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348(11): 994–1004PubMedCrossRef O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 Mar 13; 348(11): 994–1004PubMedCrossRef
68.
Zurück zum Zitat Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005 Apr 15; 103(8): 1659–69PubMedCrossRef Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005 Apr 15; 103(8): 1659–69PubMedCrossRef
69.
Zurück zum Zitat Shah NP, Kasap C, Weier C, et al. Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008 Dec 9; 14(6): 485–93PubMedCrossRef Shah NP, Kasap C, Weier C, et al. Transient potent BCRABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008 Dec 9; 14(6): 485–93PubMedCrossRef
70.
Zurück zum Zitat Nagy B, Kutikova L, Stastny M, et al. An economic evaluation of dasatinib (Sprycel®) in chronic phase chronic myeloid leukemia in central and eastern Europe [abstract no. CN8]. Value Health 2008 Nov; 11(6): A358CrossRef Nagy B, Kutikova L, Stastny M, et al. An economic evaluation of dasatinib (Sprycel®) in chronic phase chronic myeloid leukemia in central and eastern Europe [abstract no. CN8]. Value Health 2008 Nov; 11(6): A358CrossRef
71.
Zurück zum Zitat Ramirez de Arellano A, Sbarigia U, Taylor MJ, et al. Cost-effectiveness analysis of dasatinib 100 mg vs. imatinib 800 mg in patients with imatinib-resistant chronic myeloid leukemia in Spain [abstract no. PCN69]. Value Health 2010 Nov; 13(7): A264CrossRef Ramirez de Arellano A, Sbarigia U, Taylor MJ, et al. Cost-effectiveness analysis of dasatinib 100 mg vs. imatinib 800 mg in patients with imatinib-resistant chronic myeloid leukemia in Spain [abstract no. PCN69]. Value Health 2010 Nov; 13(7): A264CrossRef
72.
Zurück zum Zitat Brosa M, Taylor MJ, Staginnus U, et al. Cost-effectiveness of dasatinib (Sprycel®) vs. imatinib 800 mg/day in patients with imatinib-resistant chronic myeloid leukaemia in Spain [poster no. PHM12]. 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 Oct 20–23; Dublin Brosa M, Taylor MJ, Staginnus U, et al. Cost-effectiveness of dasatinib (Sprycel®) vs. imatinib 800 mg/day in patients with imatinib-resistant chronic myeloid leukaemia in Spain [poster no. PHM12]. 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 Oct 20–23; Dublin
73.
Zurück zum Zitat Logman JFS, Taylor MJ, Neumann K, et al. Cost-utility of dasatinib (Sprycel®) in patients after first-line failure of imatinib in chronic myeloid leukemia in Austria [poster no. PCN11]. 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 Oct 20–23; Dublin Logman JFS, Taylor MJ, Neumann K, et al. Cost-utility of dasatinib (Sprycel®) in patients after first-line failure of imatinib in chronic myeloid leukemia in Austria [poster no. PCN11]. 10th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2007 Oct 20–23; Dublin
75.
76.
Zurück zum Zitat Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for acheiving molecular responses in patients with chronic myeloid leukemia who acheive complete cytogenetic responses on imatinib. J Clin Oncol 2010 May 10; 28(14): 2381–8PubMedCrossRef Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for acheiving molecular responses in patients with chronic myeloid leukemia who acheive complete cytogenetic responses on imatinib. J Clin Oncol 2010 May 10; 28(14): 2381–8PubMedCrossRef
77.
Zurück zum Zitat Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009 May 28; 113(22): 5401–11PubMedCrossRef Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009 May 28; 113(22): 5401–11PubMedCrossRef
78.
Zurück zum Zitat Ulcickas Yood M, Oliveria SA, Hirji I, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia [abstract no. 6589]. J Clin Oncol 2011; 29 Suppl. Plus poster presented at the American Society of Clinical Oncology 2011 Annual Meeting; 2011 June 3–7; Chicago (IL) Ulcickas Yood M, Oliveria SA, Hirji I, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia [abstract no. 6589]. J Clin Oncol 2011; 29 Suppl. Plus poster presented at the American Society of Clinical Oncology 2011 Annual Meeting; 2011 June 3–7; Chicago (IL)
Metadaten
Titel
Dasatinib
A Review of its Use in the Treatment of Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
verfasst von
Paul L. McCormack
Susan J. Keam
Publikationsdatum
01.09.2011
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 13/2011
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/11207580-000000000-00000

Weitere Artikel der Ausgabe 13/2011

Drugs 13/2011 Zur Ausgabe

Adis Drug Profile

Pirfenidone

Adis Drug Evaluation

Ustekinumab

Adis Drug Evaluation

Eldecalcitol